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Preventing cell entry of human immunodeﬁciency virus 1 (HIV-1) is of interest for the development
of innovative therapies. We previously reported a speciﬁc interaction between HIV-1 envelope gly-
coprotein 120 (gp120) and Tat at the cell surface, which enhances virus attachment and entry. We
also identiﬁed a gp120-mimicking peptide, CT319, that competes with gp120 for Tat binding, thus
inhibiting HIV-1 infection. Here we report a molecular dissection of gp120 regions involved in this
mechanism. Our ﬁndings identify the V1/V2 loop of gp120 as involved in Tat binding, and deﬁne this
interaction as functionally relevant for HIV-1 entry into host cells.
Structured digital abstract:
Tat physically interacts with gp120 by pull down (1, 2, 3, 4)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Blocking the initial steps of HIV-1 infection is a promising ap-
proach for innovative antiretroviral therapies. The classic pathway
of HIV-1 infection starts with a high-afﬁnity binding of the viral
envelope glycoprotein 120 (gp120) to the cell surface receptor
CD4 [1–3]; this event induces conformational changes in gp120
that expose structural elements for the recognition of the corecep-
tor chemokine (CXC-motif) receptor 4 (CXCR4) or chemokine (C–C
motif) receptor 5 (CCR5) [4–6]. Eventually, these interactions allow
the N-terminal hydrophobic portion of gp41 to insert into the host
cell plasma membrane and to induce membrane fusion [7,8].
Despite the high number of entry inhibitors being investigated,
only two have reached the market: the fusion inhibitor Enfuvirtide
(T-20, Fuzeon, Roche) [9] and the CCR5 antagonist Maraviroc (Selz-
entry/Celsentri, ViiV Helthcare) [10]; and four are currently in
phase II/III clinical trials: the CCR5 antagonists Aplaviroc (AK602/
GSK-873140, GlaxoSmithKline) [11] and Cenicriviroc (TBR-652,
Tobira Theapeutics) [12], and the attachment/post attachment
inhibitors BMS-663068 (Bristol–Myers Squibb) [13] and Ibal-izumab (TNX-355, TaiMed Biologics) [14]. All these compounds,
however, suffer of drawbacks related to drug resistance and to
the fact that most of them are strain-speciﬁc, thus limiting their
efﬁcacy in the whole population of HIV-1-infected patients. The
development of new, broad spectrum entry inhibitors remains
therefore an important medical need.
In this growing ﬁeld of investigation, we provided insights into
a previously unknown mechanism: a high afﬁnity interaction be-
tween two viral proteins, gp120 and Tat, occurs at the surface of
uninfected cell and leads to enhanced HIV-1 infectivity [15]. Tat
was ﬁrst identiﬁed as a transactivator of viral transcription [16];
however, this protein can also be secreted [17,18], exploiting sev-
eral effects while in the extracellular environment [19,20]. Soluble
Tat is partially sequestered by heparan sulfate proteoglycans, thus
being concentrated on the cell surfaces and protected from prote-
olytic degradation [19,21,22]. Gp120 constitutes the surface unit of
HIV-1 [23], being present on the viral particles as a heterotrimer
non-covalently associated with three gp41 subunits. Gp120 is
characterized by 5 regions, conserved among different viral strains
(C1–C5), and by 5 variable regions (V1–V5) [24]; the presence of
intramolecular disulﬁde bonds in the latter allows the formation
of loop-like structures [25]. We mapped the gp120-interacting site
in Tat, and we described a gp120-mimicking peptide, namely
CT319, that mimics a portion of gp120 and inhibits HIV-1 entry
through interference with gp120/Tat binding [15].
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in gp120, showing that the V1/V2 loop is indispensable for Tat
binding and cell entry, and that a basic stretch in this region is
responsible for Tat afﬁnity and viral infectivity.
2. Materials and methods
2.1. Reagents and cell cultures
The following reagents were provided by the Programme Euro-
pean Vaccine against AIDS (EVA)/Centre for AIDS Reagents (CFAR)
at the National Institute for Biological Standards and Controls (NIB-
SC), supported by the European Community Frame Programme 6/7
(ECFP6/7) EuropriseNetworkof Excellence,AIDSVaccine Integrated
Project (AVIP) and Next Generation HIV-1 Immunogens inducing
broadly reactive Neutralising antibodies (NGIN) Consortia, and the
Bill and Melinda Gates Global HIV Vaccine Research Cryoreposito-
ry-Collaboration for AIDS Vaccine Discovery (GHRC-CAVD) Project,
UK: anti-gp120 monoclonal antibody (ICR38/ARP388, donors Dr. J.
Cordell and Dr. C. Dean), C8166 (ARP013, donor Dr. G. Farrar), and
U937 cells (ARP012, donor Dr. G. Farrar), pCAGGS SF162 gp160 plas-
mid, coding the R5-tropic HIV-1 env [26] (ARP2125, donors Dr. L.
Stamatatos and Dr. C. Cheng-Mayer). The horseradish peroxidase
(HRP)-conjugated antibody was from Jackson Laboratories (West
Grove, PA). Peptides were from New England Peptide (Fitchburg,
MA). 293T cells (ATCC CRL-11268) were from LG Promochem (Sesto
San Giovanni, Italy). Cells were cultured in Iscove’s modiﬁed Dul-
becco’smedium(IMDM) supplementedwith10% fetal bovine serum
(FBS), 2 mM glutamine, 200 U/ml penicillin and 200 lg/ml strepto-
mycin (Lonza, Rockland, ME).
2.2. Deletion mutants of the gp120 coding sequence
Plasmids encoding deletion mutants of the gp120 protein were
generated by a combination of PCR ampliﬁcations, restriction en-
zyme digestions and fragment ligations. To delete the V1 loop,
PCR ampliﬁcations of pEnvHXB [27] were performed using the fol-
lowing primer pair combinations (Sigma–Aldrich, Milan, Italy):
A: env16 (50-TCGAGACCGGGCCTTTGT-30)
50V1 (50-GTCTGAGTCGCCGGCTCCAGTGCACTTTAAACTAACACA
GAG-3’);
B: 30V1 (50-GTCTGAGTCGCCGGCAACTGCTCTTTCAATATCAG-30)
env11 (50-TCAGTACAATCTGCTCTG-30).
The product of reaction A, digested with Sac I and Nae I, was li-
gated with the product of reaction B, digested with Nae I and Xho I,
and subcloned into pEnvHXB. To delete the V2 loop, PCR ampliﬁca-
tions were performed with the following primer pairs:
C: env16 (50-TCGAGACCGGGCCTTTGT-30)
50V2 (50-GTCTGAGTCGGATCCGGCACCAGAGCAGTTTTTTATCTC
TCC-30);
D: 30V2 (50-GTCTGAGTCGGATCCTGTAACACCTCAGTCATTACA
CAG-30)
env11 (50-TCAGTACAATCTGCTCTG-30).
The product of reaction C, digested with Sac I and Bam HI, was
ligated with the product of reaction D, digested with Bam HI and
Xho I, and subcloned into pEnvHXB. To delete the V1/V2 loop, PCR
ampliﬁcations were performed with the following primer pairs:
E: env16 (50-TCGAGACCGGGCCTTTGT-30)
50V1V2 (50-GTCTGAGTCGGATCCGGCACCAGAGCAGTTGCCGGCT
CCAGTGCAC TTTAAACTAACACAGAG-30)
F: 30V2 (50-GTCTGAGTCGGATCCTGTAACACCTCAGTCATTACA
CAG-30)
env11 (50-TCAGTACAATCTGCTCTG-30).
The product of reaction E, digested with Sac I and Bam HI, was
ligated with the product of reaction F, digested with Bam HI and
Xho I, and subcloned into pEnvHXB.2.3. Point mutants of the gp120 coding sequence
Point mutations were introduced into pEnvHXB using the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
with the following primer pairs (Sigma–Aldrich):
K168A: fw K168A (50-AGCATAAGAGGTGCGGTGCAGAAAGAA-30)
rv K168A (50-TTCTTTCTGCACCGCACCTCTTATGCT-30);
Q170A: fw Q170A (50-AGAGGTAAGGTGGCAAAAGAATATGCA-30)
rv Q170A (50-TGCATATTCTTTTGCCACCTTACCTCT-30);
K171A: fw K171A (50-GGTAAGGTGCAGGCAGAATATGCATTT-30)
rv K171A (50-AAATGCATATTCTGCCTGCACCTTACC-30);
K168A/Q170A: fw K168A/Q170A (50-AGCATAAGAGGTGCGGTG
GCAAAAGAA-30)
rv K168A/Q170A (50-TTCTTTTGCCACCGCACCTCTTATGCT-30);
K168A/K171A: this mutant was obtained using the K168A and
K171A primer pairs consecutively;
Q170A/K171A: fw Q170A/K171A (50-GGTAAGGTGGCAGCAGAA
TATGCATTT-30)
rv Q170A/K171A (50-AAATGCATATTCTGCTGCCACCTTACC-30);
K168A/Q170A/K171A:
fw K168A/Q170A/K171A (50-AGAGGTGCGGTGGCAGCAGAATAT
GCA-30)
rv K168A/Q170A/K171A (50-TGCATATTCTGCTGCCACCGCACCT
CT-30).
2.4. Production and transduction of HIV-1-derived lentiviral vectors
Gp120-pseudotyped lentiviral vectors (LVs) were produced as
previously described [15]. Brieﬂy, cotransfection was performed
in 293T (packaging) cells using the following plasmid
combinations:
Tat+/gp120-LVs [28]: pRRL.hPGK.GFP.SIN-18 + pCMVDR8.2 +
pEnvHXB.
Tat/gp120-LVs: pRRL.hPGK.GFP.SIN-18 + pMDLg/pRRE +
pRSV-Rev [29]+pEnvHXB.
R5-Tat/gp120-LVs: pRRL.hPGK.GFP.SIN-18 + pMDLg/pRRE +
pRSV-Rev + pCAGGS SF162 gp160.
After 16 h, cells were extensively washed to remove free plas-
mid DNA. Supernatants were collected 72 h post-transfection and
ﬁltered to remove any free cell and cellular debris. The number
of viral particles in these supernatants was quantiﬁed with the
HIV-1 p24 ELISA kit (Perkin Elmer, Boston, MA). Viral preparations
were used to transduce 1  105 C8166 (host) cells in the presence
of 8 lg/ml polybrene. The multiplicity of infection (MOI) was 5.5
and 1.5 for Tat/gp120-LVs and Tat+/gp120-LVs, respectively.
Treatments with recombinant Tat (7 nM) and with synthetic pep-
tides were performed as described [15]. Optimization of the pep-
tide concentrations and host cell type for the entry assays is
detailed in the Supplementary Material (Supplementary Fig. 1).
2.5. Quantiﬁcation of virus entry into host cells
LV-transduced C8166 cells were analyzed for the expression of
green ﬂuorescent protein (GFP) by cytoﬂuorimetric analysis (FAC-
SCalibur, BD Biosciences, Franklin Lakes, NJ) 72 h after infection, as
we previously described [15]. LV entry was also quantiﬁed by Real-
Time Polymerase Chain Reaction (Real-Time PCR) analysis of intra-
cellular HIV-1 transcripts 2 h after infection, adapting previously
published protocols [30,31]. Brieﬂy, cells were washed once with
phosphate buffered saline (PBS), and lysed in 100 ll of 10 mM
Tris–HCl (pH 8.3) containing 50 mM KCl, 2.5 mM MgCl2, 0.1 mg/
ml gelatin, 0.45% Nonidet P-40, 0.45% Tween 20, and 100 lg/ml
proteinase K. After protein digestion (2 h at 56 C) and inactivation
of the proteinase (10 min at 95 C), 10 ll of cell lysate was directly
subjected to Real-Time PCR using the SYBR Green PCR Master Mix
(Applied Biosystems) with the following primers:
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rv R/U5 (50-CTGCTAGAGATTTTCCACACTGAC -30) 50 nM
in a total volume of 25 ll. For each experiment, a reference
curve was prepared with serial dilutions (102 to 106 copies) of
the pRRL.hPGK.GFP.SIN-18 plasmid, and a negative control was
performed with water only. Further controls for assay optimization
are detailed in the Supplementary Material (Supplementary Fig. 2).
The reaction was carried out with an initial step at 95 C for
10 min, followed by 40 cycles of ampliﬁcation (15 s at 95 C and
1 min at 60 C) and a ﬁnal extension step (1 min at 95 C and
1 min at 55 C) in a CFX96 Real-Time PCR detection system (Bio-
Rad). Data were analyzed following the guidelines of the Real-Time
PCR Applications Guide (BioRad).
2.6. Production of recombinant proteins, pull-down and Western blot
Glutathione-S-transferase (GST) and GST-Tat86 proteins were
produced as described [15]. Brieﬂy, bacteria were pre-grown over-
night at 37 C in Terriﬁc Broth supplemented with 50 lg/ml ampi-
cillin, diluted 15-fold in this same medium, and grown at 30 C
until OD590 = 6.0. Protein production was induced with 1 mM iso-
propyl b-D-1-thiogalactopyranoside (IPTG) for 2 h at 30 C. Bacteria
were sonicated in 100 mM NaCl, 50 mM Tris–HCl, 5% glycerol,
2 mM DL-dithiothreitol (DTT). Bacterial extracts were incubated
at 4 C overnight with glutathione-Sepharose resin (GE-Healthcare,
Chalfont St. Giles, UK), followed by 4 washes in lysis buffer
[150 mM NaCl, 50 mM Tris pH 7.4, 1% Nonidet P40, 1 mM phenyl
methyl sulfonyl ﬂuoride (PMSF), and protease inhibitor cocktail
(Sigma–Aldrich)]. Gp120s were produced by transient transfection
of 293T cells with 5 lg of the corresponding plasmids using a
Mammalian Transfection Kit (Promega, Milan, Italy); after 72 h,
deriving cell lysates were obtained by extraction in lysis buffer.
For the pull-down assays, protein extracts (4 mg) were pre-cleared
on GST-resin for 1 h at 4 C. Unbound proteins were incubated with
GST-Tat86-resin for 1 h at 4 C, washed 3 times with lysis buffer
and once with phosphate-buffered saline (PBS). Bound proteins
were separated by SDS–PAGE, transferred onto polyvinylidene
ﬂuoride (PVDF) membranes (Millipore, Bedford, MA), and deco-
rated with standard procedures. Band intensity was evaluated
using Quantity One 4.6 Software (Biorad, Milan, Italy).
2.7. Statistical analysis
Two-tailed Student’s t-test was used to evaluate the differences
within experimental points (Prism 5, GraphPad Software, La Jolla,
CA). Symbols in the graphs indicate the degree of statistical signif-
icance: ⁄, § = P < 0.05, ⁄⁄, §§ = P < 0.01, ⁄⁄⁄, §§§ = P < 0.001.
3. Results
We previously described a peptide based on a consensus among
gp120 sequences from several HIV-1 strains, namely CT319 (se-
quence: CSFNITTEIRDKVKK). CT319 interferes with gp120/Tat
interaction and inhibits Tat-driven HIV-1 entry at a concentration
as low as 1 nM. We identiﬁed two functionally active sites corre-
sponding to the N-(CT303, sequence: CSFNIT) and C-terminal
(CT304, sequence: RDKVKK) portions of CT319. In binding assays
performed in vitro, gp120/Tat displacement was not increased by
adding concentrations higher than 1 mM for CT303, while CT304
showed a complete dose–response effect with an IC50 = 2 lM [15].
3.1. Molecular dissection of active sites in a gp120-mimicking peptide:
the N-terminal cysteine and the C-terminal basic stretch are necessary
for HIV-1-blocking activity.
Although the effect of CT303 in the displacement of the gp120/
Tat interaction was weak, the great (3-log) difference in the efﬁ-cacy of CT319 compared to CT304 suggested an involvement of the
N-terminal portion in the described mechanism. In a ﬁrst aspect,
therefore, this study is based on new peptides in which the N-ter-
minal cysteine of CT319 was either deleted (S14K) or replaced by
methylcysteine (Cm15K), serine (S15K), threonine (T15K), or
methionine (M15K). A variant with a supplemental cysteine at
the C-terminal (C16C) was also produced, to trigger cyclization
by the formation of an intramolecular disulﬁde bond. By mass-
spectrometry, we further observed that CT319, when maintained
in non-reducing conditions for several days, spontaneously con-
verts into a dimer (DIM), possibly by formation of intermolecular
disulﬁde bonds (data not shown). We tested the ability of all these
CT319 variants to block cell entry of viral particles that reproduce
complete HIV-1 virions while being replication-defective (Tat+/
gp120-LVs). In this system, the ﬁrst steps of HIV-1 infection are
evaluated by counting the numbers of green ﬂuorescent protein
(GFP) positive (i.e., LV-transduced) cells [15,27,28]. C8166 lym-
pho-monocytes were infected with Tat+/gp120-LVs in the presence
of each synthetic peptide (100 nM). GFP-expressing cells were
counted after 72 h, revealing that only Cm15K and C16C retain a
signiﬁcant inhibitory effect, while all the other variants of CT319
are ineffective (Fig. 1A). We further dissected the role of these pep-
tides in Tat-mediated cell entry by using a Tat-defective LV system
(Tat/gp120-LVs). C8166 cells were pretreated with medium only
or with recombinant Tat as described [15], before being infected
with Tat/gp120-LVs in the presence of each synthetic peptide
(100 nM). Viral entry was evaluated by Real-Time PCR quantiﬁca-
tion of intracellular HIV-1 transcripts after 2 h. As expected, none
of the peptides inhibited, and one (M15K) even enhanced viral en-
try in the absence of Tat. When the complete molecular circuit was
restored by the addition of recombinant Tat, a signiﬁcant inhibition
in viral entry was again achieved only by incubation with Cm15K
and C16C (Fig. 1B).
We next moved to the investigation of the C-terminal portion of
CT319, where the presence of a positively charged (basic) stretch is
in support for an involvement in electrostatic protein–protein
interactions. We obtained basic-to-alanine derivatives (n = 6) of
the CT304 sequence, and we evaluated the ability of these peptides
to interfere with virus entry. C8166 cells were incubated with Tat+/
gp120-LVs in the presence of each synthetic peptide (100 lM), and
the numbers of GFP-positive cells were counted after 72 h. In these
assays, only RDAVKA retained a weak inhibitory activity (10%),
while all the other mutants either had no effect (RDKVKA, RDAVKK,
RDAVAK), or even induced an opposite outcome (RDKVAK,
RDKVAA) (Fig. 1C). These same peptides (100 lM) were challenged
in the cell entry assay with Tat/gp120-LVs, after pretreatment
with medium only or with recombinant Tat. In this case, the
Real-Time PCR evaluation of intracellular HIV-1 DNA showed that
none of the peptides was capable of inhibiting viral entry; instead,
some of them enhanced this process, either in the absence
(RDAVKK, RDAVAK) or in the presence (RDKVAA) of Tat (Fig. 1D).
We also investigated the contribution, if any, of strain-related
variants of gp120 proteins in the inhibition of LV entry by the C-
terminal basic stretch of CT319. First, we obtained synthetic vari-
ants (n = 11) of CT304 that mimic gp120 sequences from different
HIV-1 strains (http://www.hiv.lanl.gov/), and we challenged these
peptides (100 lM) in the described entry assays with Tat-deﬁcient
LVs, either in untreated or Tat-pretreated C8166 cells. Second, in
addition to the HXB2 gp120-pesudotyped LVs (Tat/gp120-LVs),
we also prepared viral particles covered by a R5-tropic envelope,
namely the CF162 env (R5-Tat/gp120-LVs), that were tested in
similar entry experiments. Entry was evaluated both by cytoﬂuori-
metric analysis of GFP-positive cells (Fig. 2A) and by Real-Time PCR
(Fig. 2B, X4-tropic viruses; Fig. 2C. R5-tropic viruses). In the case of
X4-tropic LVs, as expected none of the peptides exerted an inhibi-
tory effect on the entry of Tat-defective gp120-LVs; when cells
Fig. 1. Molecular dissection of active sites in a HIV-1-blocking peptide: both the N- and C-terminal of CT319 contribute to LV entry inhibition. C8166 cells were infected with
HIV-1-derived virions in the presence of the indicated CT319 (CSFNITTEIRDKVKK, 100 nM) (A and B) and CT304 (RDKVKK, 100 lM) (C and D) variants. Viral entry was
evaluated by cytoﬂuorimetric analysis of GFP-expressing cells 72 h after infection (A and C) and by Real-Time PCR quantiﬁcation of HIV-1 intracellular DNA copy numbers 2 h
after infection (B and D). Statistical signiﬁcance was calculated by a two-tailed Student’s t-test and is expressed as ⁄ = P < 0.05, ⁄⁄ = P < 0.01 and ⁄⁄⁄ = P < 0.001 for the
inhibition, and § = P < 0.05, §§ = P < 0.01 and §§§ = P < 0.001 for the increase in virus entry into C8166 cells versus control infections. Values are expressed as percent variation
over control infections, and indicate mean ± S.D. of 3 experiments performed in triplicate.
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20% and 40% in the two assays, respectively, (Fig. 2A and B).
For the R5-tropic LVs, the blocking effect of all the peptide variants
in the presence of Tat was retained, leading to up to 50% inhibi-
tion in the Real-Time PCR evaluation. In some instances (i.e.,
RDKKKK, RDKKKQ, RDKKKV, RDKKQK, RDKQQK, Fig. 2C) we ob-
served a 20% inhibition of viral entry also in the absence of Tat,
suggesting that this region of the env protein might participate
in other molecular interactions/mechanisms.
Together, these data demonstrate that both the N- and C-termi-
nal portions of CT319 are involved in the inhibition of Tat-driven
cell entry of HIV-1-derived virions, and that this mechanism is
strain-independent.
3.2. The V1/V2 loop of the gp120 protein is indispensable for Tat
binding and virus entry
CT319 mimics a region spanning the V1/V2 loop and corre-
sponding to aa 157–171 of the HXB2 gp120. To investigate the role
of this sequence in the contest of the whole protein, we designed
deletion mutants lacking either the V1 (DV1-gp120) or the V2
(DV2-gp120) portions, or the entire V1/V2 (DV1/V2-gp120) loop
(Fig. 3A). The corresponding pEnvHXB plasmids were transfected
into 293T cells, in the same conditions used for producing LV par-
ticles. In this way, a correctly processed gp120 protein is present at
the cell surface [27] and can be extracted in its native conforma-
tion. Cell lysates were incubated with either GST (control) orGST-Tat86 (target) [15,32], and separated by SDS–PAGE. Tat-bound
gp120 variants were quantiﬁed by densitometric analysis of the
protein bands immunostained with an antibody against the C4 re-
gion of gp120 (aa 427–436). This assay showed that Tat binding to
both DV1- and DV2-gp120 was as low as 30%, compared to wild-
type gp120. Remarkably, DV1/V2-gp120 was almost completely
unable to interact with Tat (Fig. 3B). We also evaluated the capabil-
ity of LVs pseudotyped with the same deletion mutants of gp120 to
enter into host cells, observing that none of them is capable to en-
ter into C8166 cells, both in basal conditions and in the presence of
Tat (data not shown).
These ﬁndings demonstrate that the V1/V2 loop of gp120 is the
region responsible for speciﬁc binding to Tat; however, this region
is involved also in other aspects of cell entry, for which it is non-
dispensable.
3.3. The basic stretch in gp120-V1/V2 loop modulates Tat afﬁnity and
Tat-dependent virus entry
To dissect the molecular interactions involving the V1/V2 loop
of gp120, we focused our attention on the CT304-mimicked region,
corresponding to aa 166–171 of HXB2 gp120. We transposed all
the combinations of basic-to-alanine mutations into the coding se-
quence of gp120 (Fig. 3C), and we performed pull-down assays as
described above. A densitometric analysis of GST-Tat86-bound
gp120 proteins revealed that 4 mutants, namely K168A, K168A/
K171A, Q170A/K171A, and K168A/Q170A/K171A bind Tat with
Fig. 2. Molecular dissection of active sites in a HIV-1-blocking peptide: the inhibitory effect of the basic stretch is not dependent on the viral strain. CT304-like peptides
(100 lM) corresponding to gp120 proteins of different HIV-1 strains were challenged in viral entry assays with X4-tropic (A and B) and R5-tropic (C) Tat/gp120-LVs, in
C8166 cells either untreated or Tat-pretreated. Entry was evaluated by cytoﬂuorimetric analysis of GFP-positive cells after 72 h (A) or by Real-Time PCR after 2 h (B and C).
Statistical signiﬁcance was calculated by a two-tailed Student’s t-test and is expressed as described in Fig. 1. Experimental points are mean ± S.D. of 2 experiments performed
in triplicate.
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gp120 (Fig. 3D). We also investigated the capability of LVs pseudo-
typed with basic-to-alanine mutants of gp120 to enter into host
cells. For this purpose, we produced both Tat+/gp120-LVs and Tat/
gp120-LVs pseudotyped with each point mutant of gp120. C8166
cells were infected with the deriving virions and viral entry was
evaluated by cytoﬂuorimetric analysis of GFP-positive cells(Fig. 4A and C) and by real-time quantiﬁcation of intracellular
HIV-1 DNA copy numbers (Fig. 4B and D).
In a ﬁrst set of experiments, we tested the various Tat+/
gp120-LVs, observing that none of the mutated LVs has impaired
infectivity; on the contrary, some mutations confer the cognate
virions a weakly enhanced capability of cell entry, which was sta-
tistically signiﬁcant for K171A (both evaluations), K168A/Q170A
Fig. 3. The V1/V2 loop of gp120 is involved in Tat binding and afﬁnity. The indicated deletions (A) and point mutations (C) of the gp120 coding sequence were introduced in
pEnvHXB. The deriving plasmids were transfected into 293T cells in the same conditions used for LV production, and all the gp120 protein variants were membrane-extracted
to be challenged in pull-down assays with puriﬁed GST-Tat86 (B and D). For simplicity of visualization, in D the gp120 mutants are indicated with their corresponding amino
acid sequence (alanine substitutions are underlined), that is, wild-type: RGKVQK; K168A: RGAVQK; Q170A: RGKVAK; K171A: RGKVKA; K168A/Q170A: RGAVAK; K168A/
K171A: RGAVKA; Q170A/K171A: RGKVAA; K168A/Q170A/K171A: RGAVAA. The amounts of Tat-bound (pulled-down) gp120 variants, quantiﬁed by densitometric analysis,
were normalized on their total amounts in cell lysates, and are expressed as fold change over the wild-type protein. Statistical signiﬁcance was calculated by a two-tailed
Student’s t-test and is expressed as described in Fig. 1. Values indicate mean ± S.D. of 3 experiments.
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Q170A/K171A (Real-Time PCR) (Fig. 4A and B). Conversely, when
C8166 cells were infected with Tat/gp120-LVs, the mutations re-
sulted in either a decreased (K168A, both evaluations; K168A/
K171A, Q170A/K171A, K168A/Q170A/K171A, Real-Time PCR) or
an increased (Q170A, Real-Time PCR; K171A, K168A/Q170A both
evaluations) viral entry into host cells (Fig. 4C and D). To isolate
Tat-speciﬁc effects, we subtracted the variations in viral entry of
Tat-deﬁcient virions (Tat/gp120-LVs) from that of the complete
HIV-1 particles (Tat+/gp120-LVs) (Fig. 4E and F). This analysis re-
vealed that, in the presence of Tat, entry is increased when LVs
are pseudotyped with 4 mutant gp120 proteins (K168A, Q170A/
K171A, K168A/K171A, K168A/Q170A/K171A, both evaluations),
while it is decreased only when they are pseudotyped with the
K168A/Q170A mutant protein (both evaluations).
These ﬁndings demonstrate that different mechanisms, in-
cluded the afﬁnity of gp120 for Tat (compare Fig. 4E and F with
Fig. 3D), account for Tat- and gp120-mediated virus entry into host
cells.
4. Discussions
We here dissect the role of the gp120 V1/V2 loop in Tat binding
and in the modulation of virus entry. This analysis will be the basis
for a rational evolution of the peptide entry inhibitors that we pre-
viously described [15].
The ﬁrst part of our work is focused on the characterization of
CT319, a peptide mimicking a portion of the gp120 V1/V2 loop.
We demonstrate that the N-terminal cysteine is indispensable forthe inhibition of Tat-driven virus entry: only the variants in which
this residue is preserved retain an inhibitory effect (Fig. 1A and B).
In the native HXB2 protein, the cysteine in position 157 is involved
in a disulﬁde bond thus representing a structural component of the
V1 and V2 loops; not surprisingly, the peptide with the highest
efﬁcacy in counteracting Tat-mediated infectivity is C16C, the cy-
clized version of CT319. We next provide evidence that also the
C-terminal basic stretch of this peptide is pivotal for the inhibition
of Tat-driven virus entry: none of the basic-to-alanine variants has
an activity comparable to that of CT304 (Fig. 1C and D). In agree-
ment with our previous data [15], we also conﬁrm that the inhib-
itory effect of CT304 (and of similar peptides corresponding to this
same region in different gp120s) is independent from the viral
strain, being comparable in assays with both X4- and R5-tropic
LVs (Fig. 2). Such peptides or their small-molecule derivatives,
therefore, could be evolved in rationally designed, broadly-effec-
tive anti-HIV-1 drugs. Intriguingly, peptides from both panels have
an agonistic effect either in the presence (S14K, Fig. 1B, RDKVAK
and RDKVAA, Fig. 1C and D) or in the absence of Tat (M15K,
Fig. 1B, RDAVKK and RDAVAK, Fig. 1D). In both cases, such an out-
come may be due to several factors: mutant peptides could induce
conformational changes in gp120, interfere with other interactions
in which gp120 is involved, and/or produce off-target effects (com-
mon when short peptides are used at relatively high dose).
Further evidence for the importance of the gp120 V1/V2 loop in
Tat-related HIV-1 infectivity comes from our studies with puriﬁed
proteins and complete virions. We demonstrate that Tat binding
requires both V1 and V2 loops: indeed, DV1- and DV2-gp120 exhi-
bit a binding ability as low as 30% compared to wild-type gp120,
Fig. 4. The basic residues in the V1/V2 loop of gp120 are involved in Tat-mediated virus entry. pEnvHXB plasmids carrying point mutations in the gp120 coding sequence
were used to prepare the cognate LVs. C8166 cells were infected with all the variants of Tat+/gp120-LVs (A and B) and Tat/gp120-LVs (C and D), and cell entry was evaluated
by cytoﬂuorimetric analysis (A and C) and by Real-Time PCR (B and D). To discriminate Tat-speciﬁc effects, the percent variation in cell entry of Tat/gp120-LVs was
subtracted from that of the corresponding Tat+/gp120-LVs (E and F). For simplicity of visualization, the gp120 mutants are indicated with their corresponding amino acid
sequence (alanine substitutions are underlined) as described in Fig. 2. Statistical signiﬁcance was calculated by a two-tailed Student’s t-test and is expressed as described in
Fig. 1. Values are expressed as percent variation over infections with wild-type LVs, and indicate mean ± S.D. of 4 experiments performed in triplicate.
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pletely unable to interact with Tat (Fig. 3B). In our experiments,
the deletion of either part of the gp120 V1/V2 loop led to abroga-
tion of LV entry into host cells, as detected by counting the number
of GFP-positive cells (data not shown). Such a result goes beyondthe sole involvement of Tat, and is consistent with previous ﬁnd-
ings indicating a role for the gp120 V1/V2 loop in HIV-1 infectivity.
For example, Wyatt et al., show that a deletion mutant lacking the
V1 portion of the loop (D136–151) is defective in functions related
to infection, example, the ability of inducing cell syncytia (14% of
2950 S. Cardaci et al. / FEBS Letters 587 (2013) 2943–2951the wild-type) and of complementing virus entry into Jurkat cells
(34%). The latter function is retained at comparable levels (30%)
by the fully-deleted variant (D128–194) [33]. This residual infec-
tivity of gp120 mutants, in partial discrepancy with our results,
may be related to the experimental design, that is the detection
of a reporter activity (an ampliﬁcation system that can discrimi-
nate among little differences) versus our cytoﬂuorimetric evalua-
tion of LV-transduced cells. However, other ﬁndings are in
support for a dependence on the viral strain and/or the cell type
investigated: Cao et al., show that a HIV-1 mutant lacking the V1
and V2 variable loops of gp120 replicates in Jurkat lymphocytes
with only a weak delay; they also report the rapid emergence of
revertants containing a few amino acid changes to counteract the
effect of the deletion [34]. Stamatatos et al., observe that V1/V2
loop-deleted gp120 proteins support replication of SF162 virus into
peripheral blood mononuclear cells but not in macrophages [35].
All these complex interactions still have to be fully elucidated;
however, for the ﬁrst time we here demonstrate that the deletion
of the V1/V2 loop impacts on Tat binding to gp120, and therefore
at least part of these effects may be dependent on this molecular
circuit (e.g. the amount of membrane-bound Tat and its availabil-
ity, the presence of particular cell surface proteoglycans and/or of
peculiar coreceptors, and so on).
A molecular explanation for the role of the V1/V2 loop in HIV-1
infectivity has been partially provided in previous studies. Molec-
ular determinants in the V1/V2 loop that inﬂuence viral infectivity
are those involved in heparin binding: a study from Mbemba et al.,
demonstrates that gp120 elicits multimolecular complexes, and
that most of these interactions are abolished by heparin [36].
Accordingly, heparan sulfate-interacting sites have been identiﬁed
in the coreceptor binding site of gp120 [37] and, recently, four hep-
arin-binding domains have been mapped, including lysine 168 in
the V2 region [38]. A mutation of this residue could lead to the on-
set of a different interaction network, in which heparan sulfate or
other surface proteoglycans are not included as gp120 partners.
Such a reorganization could be responsible for changes in virus
infectivity as a possible consequence of different exposure/avail-
ability of binding sites. Consistently, our ﬁndings demonstrate that
three out of four gp120 mutants having the lysine 168 converted
into an alanine (i.e. K168A, K168A/K171A and K168A/Q170A/
K171A) have an increased capability to bind recombinant Tat
(Fig. 3D).
In an attempt to discriminate between Tat-dependent and Tat-
independent effects, we compared the entry of LVs pseudotyped
with the described basic-to-alanine mutant gp120 proteins, either
in the presence of complete HIV-1 virions or in Tat-defective con-
ditions (Fig. 4). These assays demonstrated that the four mutants
with greater afﬁnity to recombinant Tat (i.e. K168A, K168A/
K171A, Q170A/K171A and K168A/Q170A/K171A, see Fig. 3D for
comparison) also have an enhanced capability to enter into host
cells, compared to viral particles pseudotyped with the wild-type
gp120 protein. The fact that both Tat and gp120 bind to the hepa-
ran sulfates may represent one explanation of why these changes
in the basic amino acids of gp120 lead to an altered Tat-related
infectivity: this can possibly be related to an unbalance of their re-
ciprocal molecular interactions. Most remarkably, one of the gp120
mutants, that is K168A/Q170A, although retaining an afﬁnity for
Tat similar to that of the wild-type protein, appears to be pivotal
in Tat-mediated cell entry of HIV-1 virions (Fig. 4E and F), again
suggesting that features other than Tat/gp120 afﬁnity, such as ki-
netic of interaction, induction of conformational changes, and/or
recruitment of molecular partners are relevant in this context.
The group of Dr. Ensoli, the only other having published a direct
interaction between Tat and gp120, has reported results differing
from ours. In a ﬁrst set of experiments, they show that immobi-
lized Tat binds both retroviral (VSV-G pseudotyped) and lentiviral(gp120-pesudotyped) virions, thus enhancing viral transduction, as
assessed by GFP-expressing cells in cytoﬂuorimetric analysis (sim-
ilar to our system) or by p24 quantiﬁcation using a single-cycle
replication-defective virus [39]. This work shows that Tat-assisted
infection does not require binding to a speciﬁc envelope: due to the
high amounts of Tat used (micromolar range), the observed effect
should therefore be attributed to an electrostatic interaction of Tat
with the viral surface, as previously described for cell entry of
adenoviral vectors [40]. This same feature explains why Tat is efﬁ-
cient only when immobilized and not when in solution: in our pre-
vious work, we demonstrated that increasing the amount of
soluble Tat reverts its HIV-1-speciﬁc promotion of virus entry, pos-
sibly by interfering with other cellular mechanisms [15]. They fur-
ther provide some evidence that the cysteine-rich region of Tat is
required for binding to virus particles. In contrast with their ﬁrst
set of data, in a recent work they show that Tat and trimeric
gp120 interact speciﬁcally, and that this interaction is responsible
for the promotion of viral transmission in dendritic cells [41]. They
conﬁrm the involvement of the cysteine-rich domain of Tat, and
they state that the V3 loop of gp120 is involved in this binding.
Although we do not exclude an interaction of Tat cysteine region
with gp120 V3 loop (we have not investigated this region of the
envelope protein), these results need further discussion. First, they
found, by Surface Plasmon Resonance analysis, Kd values for Tat/
monomeric DV2 gp120 about 10-fold higher (9.1  108) than
those found by our group for Tat/gp120 (8.1 ± 0.3  109), an indi-
cation of lower afﬁnity. Second, again the high amounts of Tat used
might lead to a switch from the high afﬁnity Tat C-terminal/gp120
V2 loop interaction to the lower afﬁnity Tat cysteine domain/
gp120 V3 loop interaction. Third, they purify recombinant Tat by
heparin-afﬁnity columns, and therefore heparin is present (pre-
sumably in high amounts) in all the incubations: as previously dis-
cussed, the presence of heparin can unbalance interactions that
involve the V2 loop of gp120. On the contrary, our recombinant
Tat is puriﬁed either by ion-exchange columns or GST-tagged
and puriﬁed by glutathione-Sepharose beads; therefore no heparin
or similar contaminants are present in our preparations.
Finally, a brief comment on the methodology that we adopted
in this report is due. To evaluate viral entry, we applied both the
LV transduction assay (counting of GFP-positive cells) 72 h after
infection, and the quantiﬁcation of intracellular viral DNA (Real-
Time PCR) 2 h after infection. Despite being completely different
assays, they gave comparable results in all the experiments (com-
pare Fig. 1A and B; Fig. 1C and D; Fig. 4A and B; Fig. 4C and D), with
the DNA quantiﬁcation being more sensitive and thus leading to
higher variations and to a greater number of statistically signiﬁcant
experimental points. This is, in our knowledge, the ﬁrst comparison
of two methods deriving from different investigation ﬁelds, that is,
gene therapy (LV-transduction) and HIV-1 diagnostic (cDNA copy
number); our results demonstrate that these methods are inter-
changeable and could be used indifferently, based on the experi-
mental setting being investigated.
In summary, our ﬁndings conﬁrm that the V1/V2 loop of gp120
is involved in complex interactions as well as in pivotal conforma-
tional changes, part of which are related to its interaction with Tat.
Our results point to a complex and modulated system, in which
molecules both on the viral and on the cellular side exploit differ-
ent functions and interact with different partners. A complete
explanation of this picture will aid the development of ‘‘smart bul-
lets’’ for the therapy of HIV-1.
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